Opsynvi

People living with pulmonary arterial hypertension (PAH) previously had to treat their disease by taking multiple treatments to address the multiple pathways that might be worsening their disease. Instead, Opsynvi offered a 2-in-1 option—and we helped by building their DTC US launch.